ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Portland, OR, USA:

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Biological: Best Available Therapy (BAT)
Procedure: Autologous Hematopoietic Stem Cell Transplantation

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Portland, Oregon, United States and 18 other locations

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Portland, Oregon, United States and 73 other locations

feasibility of a stationary aerobic cycling intervention and explore if aerobic exercise independently promotes remyelination in people with multiple...

Enrolling
Sclerosis
Multiple Sclerosis
Behavioral: Education Group Control
Behavioral: Aerobic exercise

Phase 1, Phase 2

Oregon Health & Science University (OHSU)
Oregon Health & Science University (OHSU)

Portland, Oregon, United States

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Portland, Oregon, United States and 208 other locations

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple...

Enrolling
Multiple Sclerosis
Drug: CC-97540
Drug: Cyclophosphamide

Phase 1

Juno Therapeutics

Portland, Oregon, United States and 34 other locations

relapse rate (ARR) in participants with relapsing forms of MSSecondary Objective:To assess efficacy of SAR442168 compared to teriflunomide (...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo to match Tolebrutinib
Drug: Teriflunomide HMR1726

Phase 3

Sanofi
Sanofi

Portland, Oregon, United States and 178 other locations

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple...

Active, not recruiting
Multiple Sclerosis, Primary Progressive
Drug: Placebo matched to ocrelizumab
Drug: Fenebrutinib

Phase 3

Roche
Roche

Portland, Oregon, United States and 192 other locations

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple...

Enrolling
Primary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo

Phase 3

Sanofi
Sanofi

Portland, Oregon, United States and 291 other locations

) neo-antigen in subjects with relapsing multiple sclerosis (RMS)....

Enrolling
Relapsing Multiple Sclerosis
Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Portland, Oregon, United States and 301 other locations

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMSSecondary Objective:To evalu...

Active, not recruiting
Secondary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo to match Tolebrutinib

Phase 3

Sanofi
Sanofi

Portland, Oregon, United States and 300 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems